Becton Dickinson ROE 2010-2024 | BDX
Current and historical return on equity (ROE) values for Becton Dickinson (BDX) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Becton Dickinson ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-12-31 |
$1.73B |
$25.21B |
6.73% |
| 2024-09-30 |
$1.71B |
$25.89B |
6.64% |
| 2024-06-30 |
$1.41B |
$25.87B |
5.51% |
| 2024-03-31 |
$1.32B |
$25.65B |
5.13% |
| 2023-12-31 |
$1.22B |
$25.33B |
4.75% |
| 2023-09-30 |
$1.42B |
$25.80B |
5.54% |
| 2023-06-30 |
$1.58B |
$25.94B |
6.18% |
| 2023-03-31 |
$1.53B |
$25.69B |
5.99% |
| 2022-12-31 |
$1.52B |
$25.47B |
6.03% |
| 2022-09-30 |
$1.69B |
$25.28B |
6.79% |
| 2022-06-30 |
$1.67B |
$25.49B |
6.81% |
| 2022-03-31 |
$1.83B |
$24.53B |
7.59% |
| 2021-12-31 |
$1.68B |
$24.16B |
6.93% |
| 2021-09-30 |
$2.00B |
$23.68B |
8.23% |
| 2021-06-30 |
$1.87B |
$24.14B |
7.66% |
| 2021-03-31 |
$1.64B |
$24.83B |
6.74% |
| 2020-12-31 |
$1.51B |
$24.66B |
6.46% |
| 2020-09-30 |
$0.77B |
$23.77B |
3.41% |
| 2020-06-30 |
$0.79B |
$24.02B |
3.61% |
| 2020-03-31 |
$0.92B |
$20.95B |
4.36% |
| 2019-12-31 |
$0.76B |
$21.20B |
3.57% |
| 2019-09-30 |
$1.08B |
$21.08B |
5.07% |
| 2019-06-30 |
$0.78B |
$21.50B |
3.68% |
| 2019-03-31 |
$0.93B |
$21.31B |
4.36% |
| 2018-12-31 |
$0.90B |
$21.40B |
4.22% |
| 2018-09-30 |
$0.16B |
$20.99B |
0.75% |
| 2018-06-30 |
$0.62B |
$21.36B |
3.24% |
| 2018-03-31 |
$-0.10B |
$21.15B |
-0.59% |
| 2017-12-31 |
$0.29B |
$21.25B |
2.15% |
| 2017-09-30 |
$1.03B |
$12.95B |
10.03% |
| 2017-06-30 |
$0.76B |
$12.59B |
8.50% |
| 2017-03-31 |
$1.32B |
$7.96B |
16.85% |
| 2016-12-31 |
$1.31B |
$7.58B |
16.94% |
| 2016-09-30 |
$0.98B |
$7.63B |
12.78% |
| 2016-06-30 |
$1.14B |
$8.03B |
15.13% |
| 2016-03-31 |
$0.81B |
$7.67B |
11.06% |
| 2015-12-31 |
$0.69B |
$7.22B |
9.56% |
| 2015-09-30 |
$0.70B |
$7.16B |
10.43% |
| 2015-06-30 |
$0.82B |
$7.25B |
13.29% |
| 2015-03-31 |
$1.08B |
$7.16B |
19.05% |
| 2014-12-31 |
$1.15B |
$5.07B |
22.10% |
| 2014-09-30 |
$1.19B |
$5.05B |
22.76% |
| 2014-06-30 |
$0.97B |
$5.38B |
18.72% |
| 2014-03-31 |
$0.95B |
$5.32B |
18.86% |
| 2013-12-31 |
$0.94B |
$5.08B |
19.33% |
| 2013-09-30 |
$1.29B |
$5.04B |
27.48% |
| 2013-06-30 |
$1.49B |
$4.72B |
33.32% |
| 2013-03-31 |
$1.52B |
$4.59B |
34.82% |
| 2012-12-31 |
$1.53B |
$4.47B |
35.39% |
| 2012-09-30 |
$1.17B |
$4.14B |
26.63% |
| 2012-06-30 |
$1.18B |
$4.24B |
25.86% |
| 2012-03-31 |
$1.20B |
$4.48B |
24.77% |
| 2011-12-31 |
$1.22B |
$4.73B |
24.42% |
| 2011-09-30 |
$1.27B |
$4.83B |
25.29% |
| 2011-06-30 |
$1.37B |
$5.30B |
26.42% |
| 2011-03-31 |
$1.33B |
$5.10B |
25.91% |
| 2010-12-31 |
$1.32B |
$4.88B |
25.57% |
| 2010-09-30 |
$1.32B |
$5.44B |
25.11% |
| 2010-06-30 |
$1.24B |
$5.15B |
23.91% |
| 2010-03-31 |
$1.27B |
$5.15B |
24.50% |
| 2009-12-31 |
$1.24B |
$5.26B |
24.19% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$66.130B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
